News & Insights
In this unique one-hour webinar, Dr. Jena outlines a broader framework for assessing value to improve identification of not only the highest-value treatments, but also low-value therapies on which spending can safely be reduced.
Precision will be attending the 2019 World Pharma Pricing & Market Access Congress on March 19th and 20th in Amsterdam!
In addition to visiting our sponsor booth, we encourage you to attend Precision thought leaders Basmah Khogeer and Nusayba Anjarwalla’s research presentation—full details follow:
Continuing to provide the highest level of thought leadership to healthcare innovators, Precision has been asked by the AMCP to lead a special corporate training program on unlocking opportunities in value-based contracting.
As the spotlight on manufacturers' raising the prices of therapies already on the market shows no sign of dimming, one industry group recently unveiled its intentions to dig a little deeper into the topic. The Institute for Clinical and Economic Review (ICER) says it will create a series of so-called Unsupported Price Increase (UPI) reports that will examine whether price increases are justified.
We are pleased to announce that Precision's Chief Scientist Dr. Jeroen Jansen will be participating in a special workshop organized by ISPOR on the topic of value assessments. The workshop, part of ISPOR's ongoing Summit Series, will take place on Thursday, February 28th, 2019 at 12:00pm EST. Entitled Novel Approaches to Value Assessment, WITHIN the Cost-Effectiveness Framework, this webinar will feature a video presentation from Dr. Jansen as well as a live Q&A session at the conclusion with moderator Lou Garrison, PhD.
In a featured article for PM360, Precision’s Ross Maclean and Phil Cyr identify three themes and eight interrelated factors which, if overlooked, can negatively impact a launch. In short, prescribers remain Very Important People in a launch, facing challenges around Vulnerability, Incentives, and Personalization.
Precision Xtract, part of Precision Value & Health, today announced Zac Stillerman, acclaimed healthcare industry operator and strategist, as new president and general manager. Responsible for leading Precision Xtract through its next phase of growth, Stillerman has a proven ability to translate vision and strategy into dynamic collaboration and first-class execution. He joins Precision Xtract at a time of growing demand from innovative life sciences companies for essential consulting activities, including health economic outcomes research, value demonstration, pricing and market access, and commercialization.
Led by Caroline Huber, associate director of policy and economics, a study published in The Journal of Infectious Diseases provides valuable new data on the social, economic, and health impacts of the 2013-2016 West Africa Ebola crisis.
Precision Xtract was proud to be a sponsor and featured presenter at the Real-World Data & Life Science Analytics Conference October 25-26 in Boston.
Precision will be in Barcelona November 12-13 with more than a dozen experts in health economics value demonstration, pricing & market access, and commercialization in attendance. We'll be there to talk with you and share our expertise.
Precision's thought leaders will be active throughout ISPOR, presenting their latest research in a variety of short courses, posters, issue panels and workshops. A complete list of scientific presentations can be found below:
Discover exactly what Precision can do for you. We look forward to learning about your needs, exploring how we can support you, and sharing our proven approaches. For information and inquiries, please contact:
President and General Manager+1 240.316.3451
Larry Blandford, PharmD
Executive Vice President and Managing Partner+1 212.686.2650
J. Bruce Leavitt, MBA
Executive Vice President and Managing Partner+1 203.487.5240
Ross Maclean, MD, PHD, MBA
Senior Vice President and Head of Medical Affairs+1 310.984.7708